Clinical trials: Stage III Skin Cancer
Breast Cancer
Breath Test for Women Receiving Tamoxifen in the Prevention or Treatment of Breast Cancer
RATIONALE: A breath test that measures enzymes may be effective in identifying women in whom tamoxifen may not be effective. PURPOSE: This clinical trial is studying a breath test to see how well it works in women receiving…
- Trial name
- NCT00873366
- Testing
- dextromethorphan hydrobromide, tamoxifen citrate, high performance liquid chromatography
- Where
- 2 sites in United States
- Volunteers
- 92 people
- Sponsor
- Mayo Clinic
Breast Cancer, Capecitabine
Metronomic Chemotherapy of Capecitabine After Standard Adjuvant Chemotherapy in Operable Triple Negative Breast Cancer
A Multi-center, III Phase,Randomized Controlled Clinical Study of Capecitabine Metronomic Chemotherapy After Standard Adjuvant Chemotherapy in Operable Triple Negative Breast Cancer
- Conditions
- Breast Cancer, Capecitabine, Triple Negative Breast Cancer
- Trial name
- MACRO (NCT02012634)
- Where
- China
- Volunteers
- 340 people
- Sponsor
- Xijing Hospital
Advanced Malignant Solid Neoplasm, Carcinoma of Unknown Primary
Pembrolizumab in Treating Patients With Rare Tumors That Cannot Be Removed by Surgery or Are Metastatic
This phase II trial studies how well pembrolizumab works in treating patients with rare tumors that cannot be removed by surgery or have spread to other parts of the body.
- Conditions
- Advanced Malignant Solid Neoplasm, Carcinoma of Unknown Primary, Metastatic Adrenal Gland Pheochromocytoma, Metastatic Kidney Medullary Carcinoma
- Trial name
- NCT02721732
- Testing
- Laboratory Biomarker Analysis, Pembrolizumab, Questionnaire Administration
- Where
- United States
- Volunteers
- 157 people
- Sponsor
- M.D. Anderson Cancer Center
Breast Cancer
Docetaxel, Doxorubicin and Cyclophosphamide Versus Vinorelbine and Capecitabine in Patients Not Sufficiently / Sufficiently Responding as Preoperative Treatment of Locally Advanced or Operable Primary Breast Cancer
Primary objective of the study in patients without a sufficient sonographic response (i.e. iNC) to 2 cycles of TAC as preoperative treatment of operable (T>/= 2cm, N0-2,M0) primary breast cancer: To determine the response rate…
- Trial name
- GeparTrio (NCT00544765)
- Testing
- TAC, NX
- Volunteers
- 2,014 people
- Sponsor
- GBG Forschungs GmbH
Breast Cancer
Post-operative Radiation With IMRT in the Management of Stage IIB-III Breast Cancer
Research has shown that treatment with conventional radiation techniques and chemotherapy following mastectomy or breast conserving surgery has resulted in better rates of locoregional control and overall survival in stage…
- Trial name
- NCT00508352
- Testing
- Helical tomotherapy IMRT
- Where
- Canada
- Volunteers
- 30 people
- Sponsor
- Ottawa Hospital Research Institute
Ductal Breast Carcinoma in Situ, Breast Cancer, Stage I
Effect of Omega 3 on Atrophic Vaginitis in Breast Cancer Survivors
This randomized double-blind clinical trial studied the effect of oral omega-3 fatty acid on atrophic vaginitis in postmenopausal breast cancer survivors (N=52).
- Conditions
- Ductal Breast Carcinoma in Situ, Breast Cancer, Stage I, Breast Cancer, Stage II, Breast Cancer, Stage III
- Trial name
- NCT02150525
- Testing
- omega-3 fatty acid, Questionnaire administration
- Where
- United States
- Volunteers
- 52 people
- Sponsor
- Ohio State University Comprehensive Cancer Center
Triple-negative Breast Cancer
A Study to Investigate Atezolizumab and Chemotherapy Compared With Placebo and Chemotherapy in the Neoadjuvant Setting in Participants With Early Stage Triple Negative Breast Cancer
This is a global Phase III, double-blind, randomized, placebo-controlled study designed to evaluate the efficacy and safety of neoadjuvant treatment with atezolizumab (anti-programmed death-ligand 1 [anti-PD-L1] antibody) and…
- Trial name
- IMpassion031 (NCT03197935)
- Testing
- Atezolizumab (MPDL3280A), an engineered anti-PDL1 antibody, Nab-paclitaxel, Doxorubicin
- Where
- 68 sites in United States, Australia and 11 more
- Volunteers
- 333 people
- Sponsor
- Hoffmann-La Roche
Melanoma
Phase II Biomarker Study Comparing the Combination of BRAF Inhibitor Dabrafenib With MEK Inhibitor Trametinib Versus the Combination After Monotherapy With Dabrafenib or Trametinib
This is a three-arm, open-label, randomised Phase II study to evaluate whether the different sequencing of dabrafenib and trametinib monotherapies and the upfront combination has an impact on translational or clinical activity in…
- Trial name
- NCT02314143
- Testing
- Dabrafenib, Trametinib
- Where
- 7 sites in France, Spain
- Volunteers
- 48 people
- Sponsor
- GlaxoSmithKline
Breast Cancer
Studying Blood and Tumor Tissue Samples in Women With Invasive Breast Cancer, Ductal or Lobular Carcinoma in Situ, or Benign Breast Disease
RATIONALE: Collecting and storing samples of blood and tumor tissue from patients with cancer to test in the laboratory may help the study of cancer in the future.
- Trial name
- NCT00898508
- Testing
- gene expression analysis, mutation analysis, proteomic profiling
- Where
- 3 sites in United States
- Volunteers
- 563 people
- Sponsor
- City of Hope Medical Center
Melanoma
A Phase II Study of High Dose Bolus IL2 in Patients With Inoperable Stage III or Stage IV Melanoma Who Have Failed Prior Anti-PD1 Immunotherapy: Efficacy and Biomarker Study
This study is for patients with advanced stage III or stage IV melanoma not adequately treated by surgery who have progressed after treatment with nivolumab or pembrolizumab.
- Trial name
- NCT02796352
- Testing
- High dose bolus interleukin-2 (HD IL2)
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Ahmad Tarhini
Breast Neoplasms
Combination Chemotherapy With or Without Trastuzumab in Treating Women With Breast Cancer
Primary objective: Compare disease-free survival in women with human epidermal growth factor receptor 2 (HER2)-neu-expressing node-positive or high-risk node-negative operable breast cancer treated with adjuvant doxorubicin…
- Trial name
- NCT00021255
- Testing
- Doxorubicin, Cyclophosphamide, Docetaxel
- Where
- 42 sites in United States, Argentina and 40 more
- Volunteers
- 3,222 people
- Sponsor
- Sanofi
Cancer
Natural History Study of Fungal Infections of the Blood in Patients With Cancer or in Patients Who Have Undergone a Stem Cell Transplant
RATIONALE: Gathering information about how often fungal infections of the blood occur in patients with cancer or in patients who have undergone stem cell transplant may help doctors learn more about the disease.
- Trial name
- NCT00445952
- Testing
- clinical observation, management of therapy complications
- Where
- 5 sites in Belgium, France and 3 more
- Volunteers
- 304 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Breast Cancer, Hot Flashes
Pregabalin in Treating Women With Hot Flashes
RATIONALE: Pregabalin may help relieve hot flashes in women with a history of breast cancer or those who have no history and do not wish to take estrogen therapy for fear of increased risk of breast cancer.
- Trial name
- NCT00702949
- Testing
- pregabalin
- Where
- 209 sites in United States
- Volunteers
- 207 people, healthy volunteers welcome
- Sponsor
- Alliance for Clinical Trials in Oncology
Advanced Breast Cancer
A Study of XZP-3287 in Combination With Fulvestrant in Patients With Advanced Breast Cancer
This is a phase III clinical trial to evaluate the efficacy and safety of XZP-3287 in combination with Fulvestrant versus placebo combined with Fulvestrant in Patients who have HR positive and Her2 negative recurrent/metastatic…
- Trial name
- NCT05077449
- Testing
- XZP-3287+Fulvestrant
- Where
- China
- Volunteers
- 300 people
- Sponsor
- Xuanzhu Biopharmaceutical Co., Ltd.
Cancer, Breast Cancer
Add-Aspirin: A Trial Assessing the Effects of Aspirin on Disease Recurrence and Survival After Primary Therapy in Common Non Metastatic Solid Tumours
Add-Aspirin aims to assess whether regular aspirin use after standard curative therapy can prevent recurrence and improve survival in individuals with non-metastatic common tumours.
- Conditions
- Cancer, Breast Cancer, Prostate Cancer, Colorectal Cancer
- Trial name
- NCT02804815
- Testing
- Aspirin 100mg, Aspirin 300mg
- Where
- 82 sites in Ireland, United Kingdom
- Volunteers
- 11,000 people
- Sponsor
- University College, London
Patients With Intransit Stage III/IV Melanoma
Phase 1 Dose-finding Study of L19TNFα Plus Melphalan Using Isolated Inferior Limb Perfusion (ILP) in Subjects With Intransit Stage III/IV Melanoma
In this study the recombinant human fusion protein L19TNFα will be associated in ILP with the standard treatment with melphalan 10mg/l limb volume in subjects affected by stage III/IV limb melanoma.
- Trial name
- NCT01213732
- Testing
- Isolated inferior limb perfusion
- Where
- 2 sites in Italy
- Volunteers
- 19 people
- Sponsor
- Philogen S.p.A.
Breast Cancer
Efficacy and Safety of Fluzoparib Combined With Adjuvant Endocrine Therapy for HR+/HER2- SNF3-subtype Early Breast Cancer (BCTOP-L-A01)
This is a prospective, randomized, open-label phase III clinical study on the efficacy and safety of fluzoparib combined with adjuvant endocrine therapy versus adjuvant endocrine therapy for HR+/HER2- SNF3-subtype early breast…
- Trial name
- NCT05891093
- Testing
- Fluzoparib, Anastrozole, Letrozole
- Where
- 15 sites in China
- Volunteers
- 766 people
- Sponsor
- Fudan University
Breast Cancer
Trastuzumab and Exemestane in Treating Postmenopausal Women With Metastatic or Locally Advanced Breast Cancer
RATIONALE: The monoclonal antibody trastuzumab can locate breast cancer cells that have HER2 on their surface and either kill them or deliver tumor-killing substances to them without harming normal cells.
- Trial name
- NCT00057993
- Testing
- trastuzumab, exemestane
- Sponsor
- Northwestern University
HER2-positive Breast Cancer, Male Breast Cancer
Vaccine Therapy in Treating Patients With Previously Treated Stage II-III HER2-Positive Breast Cancer
The purpose of this study is to look at the safety and immune response to a vaccine used in patients previously treated for HER2 (human epidermal growth factor receptor 2) positive breast cancer.
- Conditions
- HER2-positive Breast Cancer, Male Breast Cancer, Stage II Breast Cancer, Stage IIIA Breast Cancer
- Trial name
- NCT01632332
- Testing
- HER-2/neu peptide vaccine, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- Mayo Clinic
Early Stage Breast Cancer (Stage 0-III)
Breast Cancer Patients: A Breast Cancer Rehabilitation and Exercise Laboratory
The proposed study compares the outcomes of a physical activity intervention begun at diagnosis, continuing through active cancer treatment and into six months of survivorship compared to the outcomes of a control group receiving…
- Trial name
- NCT01157130
- Testing
- Exercise Regimen
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- Nevada Cancer Institute
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.